{
  "meta": {
    "title": "49_Anti_Platelets_And_Pro_Platelets_Thrombolytics_And_Anti_Thrombolytics",
    "url": "https://brainandscalpel.vercel.app/49-anti-platelets-and-pro-platelets-thrombolytics-and-anti-thrombolytics-b1f6f150.html",
    "scrapedAt": "2025-11-30T18:17:01.535Z"
  },
  "questions": [
    {
      "text": "A 70-year-old woman came with complaints of sudden onset of pain, swelling, and redness in her left calf. She has been experiencing difficulty walking and standing for the past two days. She has a history of hypertension and high cholesterol, which is being managed with diet and medication.\n\nOn giving which of the following drugs will we need to monitor her clotting time for?",
      "choices": [
        {
          "id": 0,
          "text": "Aspirin"
        },
        {
          "id": 1,
          "text": "Heparin"
        },
        {
          "id": 2,
          "text": "Alteplase"
        },
        {
          "id": 3,
          "text": "Apixaban"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct answer: B) Heparin</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<ul>\n\t<li>When a patient is started on Heparin, an anticoagulant, it is crucial to monitor their <span class=\"customMeta\" data-dictid=\"58c17961c71692777184ab55a9c4df\">clotting</span> time to ensure the <span class=\"customMeta\" data-dictid=\"b5bd69c9791692777186a40f45ffb6\">dosage</span> is effective and safe. This is usually done by measuring the <span class=\"customMeta\" data-dictid=\"94b02f097916927771962072dbeeac\">prothrombin</span> time (PT) and <span class=\"customMeta\" data-dictid=\"0f61fd74c41692777180190320f12e\">activated partial <span class=\"customMeta\" data-dictid=\"9b51982d06169277720063c9420fbb\">thromboplastin</span> time</span> (aPTT).</li>\n\t<li>Based on her symptoms and physical exam findings, she likely has <span class=\"customMeta\" data-dictid=\"712bb2d2b716927771867d5505033c\">deep <span class=\"customMeta\" data-dictid=\"75ddd4cc7016927772012e0acd424d\">vein</span> thrombosis</span> (DVT) in her left leg.</li>\n\t<li>Hence, an <span class=\"customMeta\" data-dictid=\"b5fc7729f316927771817f809648f5\">anticoagulant</span> like <span class=\"customMeta\" data-dictid=\"050e27829716927771885eddb2620c\">Heparin</span> should be started immediately to prevent the <span class=\"customMeta\" data-dictid=\"5e0b40993316927771844dbf382689\">clot</span> from growing or breaking off and travelling to the lungs (pulmonary embolism).</li>\n\t<li>Lepirudin (used in Heparin-Induced Thrombocytopenia) also requires aPTT monitoring</li>\n</ul>\n\n<p> </p>\n\n<p><strong>Aspirin (Option A): </strong> is an <span class=\"customMeta\" data-dictid=\"257da9409416927771815e64ee5df1\">antiplatelet</span> drug that does not require regular monitoring of <span class=\"customMeta\" data-dictid=\"58c17961c71692777184ab55a9c4df\">clotting</span> time. When given, it requires monitoring of <span class=\"customMeta\" data-dictid=\"41e858bf2816927771836d46c619b9\">bleeding</span> time.</p>\n\n<p><strong>Alteplase</strong><strong> (Options C): </strong> is a <span class=\"customMeta\" data-dictid=\"78e1197ee31692777200fa8819cf74\">thrombolytic</span> agents used to dissolve clots but monitoring of <span class=\"customMeta\" data-dictid=\"58c17961c71692777184ab55a9c4df\">clotting</span> time is not typically part of their standard administration protocol. Instead, they require careful monitoring of the patient’s overall condition and signs of bleeding. Further, when given, its action can be monitored using D- <span class=\"customMeta\" data-dictid=\"15131f1b0a1692777186cd434919ce\">Dimer</span> to detect the <span class=\"customMeta\" data-dictid=\"d395f610461692777185cbe8b8806d\">degradation</span> product of fibrin.</p>\n\n<p><strong>Apixaban (Option D)</strong> is an oral direct factor Xa <span class=\"customMeta\" data-dictid=\"b5fb56a28b1692777190396ae8b625\">inhibitor</span> that prevents <span class=\"customMeta\" data-dictid=\"ac7e1f394f1692777200c5bb11e4d8\">thrombin</span> generation and <span class=\"customMeta\" data-dictid=\"5e0b40993316927771844dbf382689\">clot</span> formation, with no routine monitoring of <span class=\"customMeta\" data-dictid=\"58c17961c71692777184ab55a9c4df\">clotting</span> time required, though <span class=\"customMeta\" data-dictid=\"b9356afdba16927771979d068c6587\">renal</span> function and <span class=\"customMeta\" data-dictid=\"41e858bf2816927771836d46c619b9\">bleeding</span> risk should be periodically assessed.</p>\n\n<p> </p>\n\n<p style=\"text-align:center\"><img alt=\"\" data-author=\"\" data-hash=\"\" data-license=\"\" data-source=\"\" data-tags=\"\" height=\"592\" src=\"https://image.prepladder.com/content/UurFmSyBXU8bYvCEfnmH1724134747.jpg\" width=\"592\" /></p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [
        "https://image.prepladder.com/content/UurFmSyBXU8bYvCEfnmH1724134747.jpg"
      ],
      "explanation_audio_eng": "https://image.prepladder.com/content/M4Go2Bs1BuCCi9Tjulxh1749057419.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/Sh5T7TMMbNAQpMCkj0F01749057368.mp3"
    },
    {
      "text": "A 58-year-old female patient with a history of atrial fibrillation visits for routine follow-up. She has been prescribed an antiplatelet drug to reduce her risk of stroke. Her medication regimen includes clopidogrel, which she has been taking for the past six months without any adverse effects. Which receptor is primarily targeted by clopidogrel to inhibit platelet aggregation?",
      "choices": [
        {
          "id": 0,
          "text": "P2Y12 receptor"
        },
        {
          "id": 1,
          "text": "GP IIb/IIIa receptor"
        },
        {
          "id": 2,
          "text": "COX-1 enzyme"
        },
        {
          "id": 3,
          "text": "Thrombin receptor"
        }
      ],
      "correct_choice_id": 0,
      "solution": "<p><strong>Correct answer: A) P2Y12 receptor</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p><strong>Clopidogrel </strong>is an <span class=\"customMeta\" data-dictid=\"257da9409416927771815e64ee5df1\">antiplatelet</span> drug that it is used for primary <span class=\"customMeta\" data-dictid=\"bc36e9b9381692777196b5f9a2f79c\">prophylaxis</span> of MI and stroke, specifically targets the P2Y12 <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> on the surface of platelets.</p>\n\n<p>By inhibiting this receptor, clopidogrel prevents <span class=\"customMeta\" data-dictid=\"923249383b169277718076e76192c8\">ADP</span> from binding, thereby reducing <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> <span class=\"customMeta\" data-dictid=\"ba6b77f29316927771807350f86ce2\">activation</span> and aggregation, which helps to lower the risk of thrombotic events such as stroke in patients with atrial fibrillation.</p>\n\n<p><strong>Normal Action of Platelets:</strong></p>\n\n<p style=\"text-align:center\"><img alt=\"\" data-author=\"\" data-hash=\"\" data-license=\"\" data-source=\"\" data-tags=\"\" height=\"700\" src=\"https://image.prepladder.com/content/bavUtsN4bL6Ip91rJg7y1724134811.jpg\" width=\"636\" /></p>\n\n<p><strong>Antiplatelet drugs</strong> are grouped into different categories based on the <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> on which they act: <strong>(Option B and C ruled out)</strong></p>\n\n<p style=\"text-align:center\"><img alt=\"\" data-author=\"\" data-hash=\"\" data-license=\"\" data-source=\"\" data-tags=\"\" height=\"479\" src=\"https://image.prepladder.com/content/rgeRMbiKRxTf6gIZGjK11724134847.jpg\" width=\"600\" /></p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [
        "https://image.prepladder.com/content/bavUtsN4bL6Ip91rJg7y1724134811.jpg"
      ],
      "explanation_audio_eng": "https://image.prepladder.com/content/NBmDuokT0S6JcgIS2pFk1749057518.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/9i8fWItsuLIy7NwRI00p1749057468.mp3"
    },
    {
      "text": "A 65-year-old male presents with acute chest pain suggestive of MI. He has a history of hypertension, hyperlipidemia, and type 2 diabetes mellitus. Which of the following is the most appropriate initial dose of aspirin for this patient?",
      "choices": [
        {
          "id": 0,
          "text": "75 mg orally"
        },
        {
          "id": 1,
          "text": "150 mg orally"
        },
        {
          "id": 2,
          "text": "325 mg orally"
        },
        {
          "id": 3,
          "text": "500 mg orally"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct answer: C) 325 mg orally</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<ul>\n\t<li>In <span class=\"customMeta\" data-dictid=\"4cdc8161f71692777180df58cafa93\">acute</span> myocardial infarction, the recommended initial dose of <span class=\"customMeta\" data-dictid=\"deba671f4716927771828c95a320e5\">aspirin</span> is <strong>160-325 mg,</strong> administered orally as soon as possible.</li>\n\t<li>This dose helps to quickly and significantly <span class=\"customMeta\" data-dictid=\"6b3de87b7c16927771901326efbcd2\">inhibit</span> <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> <span class=\"customMeta\" data-dictid=\"96309dcb1c169277720072ad555473\">thromboxane</span> <span class=\"customMeta\" data-dictid=\"3fda45538a1692777199ec2a5478a5\">synthesis</span> which leads to <span class=\"customMeta\" data-dictid=\"10c83adb331692777197f775bec1aa\">reduced</span> <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> attachment.</li>\n</ul>\n\n<p> </p>\n\n<ul>\n\t<li><strong>Dosage of Aspirin:</strong></li>\n</ul>\n\n<ol>\n\t<li>Acute MI and Stroke - 325 mg orally (Loading dose for MI)</li>\n\t<li>Secondary prevention - 75-150 mg orally (Low dose aspirin)</li>\n</ol>\n\n<p> </p>\n\n<p><strong>75 mg (Option A)</strong> is more suitable for long-term secondary prevention</p>\n\n<p><strong>150 mg (Option B)</strong> is not commonly used as an initial dose in this context.</p>\n\n<p><strong>500 mg (Option D)</strong> is not recommended as it exceeds the <span class=\"customMeta\" data-dictid=\"be786855a41692777186ef9937ebd6\">effective dose</span> range without additional benefit.</p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/NLVnIhFSqChTOy7RJaHG1749057622.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/mbBkCYUY0FX3N0DiCUO61749057577.mp3"
    },
    {
      "text": "A 72-year-old female patient with a history of atrial fibrillation and coronary artery disease is scheduled for elective hip replacement surgery in two weeks. She has been taking low-dose aspirin (75 mg daily) for secondary prevention of MI and stroke.\n\nWhich of the following is the most appropriate management regarding her aspirin therapy before surgery?",
      "choices": [
        {
          "id": 0,
          "text": "Continue aspirin at the same dose through the surgery."
        },
        {
          "id": 1,
          "text": "Stop aspirin immediately and resume after the surgery."
        },
        {
          "id": 2,
          "text": "Stop aspirin 7-10 days before surgery and resume after the surgery."
        },
        {
          "id": 3,
          "text": "Switch from aspirin to clopidogrel until after the surgery."
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct answer: C) Stop <span class=\"customMeta\" data-dictid=\"deba671f4716927771828c95a320e5\">aspirin</span> 7-10 days before surgery and resume after the surgery.</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>The patient is scheduled for <span class=\"customMeta\" data-dictid=\"37d3e89821169277718799ed0c2a19\">elective</span> surgery, which carries a risk of bleeding. Stopping <span class=\"customMeta\" data-dictid=\"deba671f4716927771828c95a320e5\">aspirin</span> 7-10 days before surgery (Option C) is recommended to allow time for new platelets to <span class=\"customMeta\" data-dictid=\"a1b06f401f1692777203a53393ba98\">form</span> (since platelets have a life span of 7-10 days), thus reducing <span class=\"customMeta\" data-dictid=\"41e858bf2816927771836d46c619b9\">bleeding</span> risk while maintaining <span class=\"customMeta\" data-dictid=\"e2b5f013011692777183ea1b11ed9c\">cardiovascular</span> protection.</p>\n\n<p><br />\n </p>\n\n<p><strong>Mechanism of Action of Aspirin: </strong></p>\n\n<p style=\"text-align:center\"><img alt=\"\" data-author=\"\" data-hash=\"\" data-license=\"\" data-source=\"\" data-tags=\"\" height=\"729\" src=\"https://image.prepladder.com/content/GiT9ngXjjZX7g8wYIWm11724134968.jpg\" width=\"500\" /></p>\n\n<p> </p>\n\n<p> </p>\n\n<p><strong>Clinical Uses and Dosage:</strong></p>\n\n<ul>\n\t<li>Aspirin is the drug of choice for\n\t<ul>\n\t\t<li>MI (Myocardial infarction)</li>\n\t\t<li>Stroke</li>\n\t\t<li>Buerger's disease</li>\n\t</ul>\n\t</li>\n\t<li>Aspirin is used in low doses (typically 75 mg daily) for long-term <span class=\"customMeta\" data-dictid=\"bc36e9b9381692777196b5f9a2f79c\">prophylaxis</span> against MI and stroke in patients with <span class=\"customMeta\" data-dictid=\"e2b5f013011692777183ea1b11ed9c\">cardiovascular</span> disease or atrial fibrillation.</li>\n\t<li>Higher doses of <span class=\"customMeta\" data-dictid=\"deba671f4716927771828c95a320e5\">aspirin</span> (160-325 mg) are used in the initial management of <span class=\"customMeta\" data-dictid=\"4cdc8161f71692777180df58cafa93\">acute</span> myocardial <span class=\"customMeta\" data-dictid=\"77aed446d2169277719007f42bf052\">infarction</span> (MI).</li>\n</ul>\n\n<p> </p>\n\n<p><strong>Precautions:</strong></p>\n\n<p><strong>Pre-surgical Considerations:</strong></p>\n\n<ul>\n\t<li>To minimise the risk of <span class=\"customMeta\" data-dictid=\"00d2d5474716927771957a22e66ad9\">perioperative</span> bleeding, it is generally recommended to stop <span class=\"customMeta\" data-dictid=\"deba671f4716927771828c95a320e5\">aspirin</span> 7-10 days before <span class=\"customMeta\" data-dictid=\"37d3e89821169277718799ed0c2a19\">elective</span> surgery to allow <span class=\"customMeta\" data-dictid=\"91229d427e169277719753f25af9f0\">regeneration</span> of platelets with normal function.</li>\n\t<li>In its place, Low <span class=\"customMeta\" data-dictid=\"b2df2436bf1692777193d90e9c0132\">Molecular Weight</span> <span class=\"customMeta\" data-dictid=\"050e27829716927771885eddb2620c\">Heparin</span> (Ex, Enoxaparin) 5000U s.c. twice dailyis used.</li>\n</ul>\n\n<p> </p>\n\n<ul>\n\t<li>Switching to clopidogrel<strong> (Option D)</strong> is not appropriate as it also affects <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> function and can increase <span class=\"customMeta\" data-dictid=\"41e858bf2816927771836d46c619b9\">bleeding</span> risk.</li>\n</ul>\n\n<p><br />\n </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [
        "https://image.prepladder.com/content/GiT9ngXjjZX7g8wYIWm11724134968.jpg"
      ],
      "explanation_audio_eng": "https://image.prepladder.com/content/eF5WdAyHTFBqAPISGXYm1749057743.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/c7XMc4oG3oT5o48gcViH1749057694.mp3"
    },
    {
      "text": "A 65-year-old male with a history of hypertension and type 2 diabetes presents with chest pain and is diagnosed with acute coronary syndrome. The cardiology team decides to initiate antiplatelet therapy. Which of the following ADP receptor blockers would be the best choice if the team wants an agent with reversible action?",
      "choices": [
        {
          "id": 0,
          "text": "Vorapaxar"
        },
        {
          "id": 1,
          "text": "Prasugrel"
        },
        {
          "id": 2,
          "text": "Ticagrelor"
        },
        {
          "id": 3,
          "text": "Ticlopidine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct answer: C) Ticagrelor</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p><strong>Ticagrelor is a <span class=\"customMeta\" data-dictid=\"a4488d66fc16927771975d043c4ccc\">reversible</span> <span class=\"customMeta\" data-dictid=\"257da9409416927771815e64ee5df1\">antiplatelet</span> agent that falls under <span class=\"customMeta\" data-dictid=\"923249383b169277718076e76192c8\">ADP</span> <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> blocker. </strong></p>\n\n<p> </p>\n\n<p><strong>ADP <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> blockers </strong>are a class of <span class=\"customMeta\" data-dictid=\"257da9409416927771815e64ee5df1\">antiplatelet</span> agents that <span class=\"customMeta\" data-dictid=\"6b3de87b7c16927771901326efbcd2\">inhibit</span> the P2Y12 <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> on platelets, thus preventing <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> aggregation.</p>\n\n<ul>\n\t<li>These drugs are commonly used in the management of <span class=\"customMeta\" data-dictid=\"4cdc8161f71692777180df58cafa93\">acute</span> <span class=\"customMeta\" data-dictid=\"bc8bc758371692777185eff2ccabb7\">coronary</span> syndrome and other <span class=\"customMeta\" data-dictid=\"e2b5f013011692777183ea1b11ed9c\">cardiovascular</span> conditions to reduce the risk of thrombotic events.</li>\n\t<li>The <span class=\"customMeta\" data-dictid=\"923249383b169277718076e76192c8\">ADP</span> <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> blockers can be categorized into <span class=\"customMeta\" data-dictid=\"a4488d66fc16927771975d043c4ccc\">reversible</span> and <span class=\"customMeta\" data-dictid=\"ee77d507701692777190bfcf47b497\">irreversible</span> agents, which differ in their duration of action and the binding nature to the P2Y12 receptor.</li>\n\t<li><strong>Irreversible blockers</strong> - permanently bind to the P2Y12 <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> on the <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> surface. Once a <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> is affected, it remains inhibited for its lifespan.</li>\n\t<li><strong>Reversible blockers </strong>- bind to the P2Y12 <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> in a <span class=\"customMeta\" data-dictid=\"a4488d66fc16927771975d043c4ccc\">reversible</span> manner, allowing for a quicker offset of action if needed.</li>\n</ul>\n\n<p><strong>Vorapaxar (Option A)</strong> (PAR 1 blocker) also has <span class=\"customMeta\" data-dictid=\"a4488d66fc16927771975d043c4ccc\">reversible</span> action.</p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Irreversible blockers (prodrugs)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Reversible blockers (active drugs)</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Ticlodipine.<strong>(Option D)</strong></li>\n\t\t\t\t<li>Clopidogrel</li>\n\t\t\t\t<li>Prasugrel.<strong>(Option B)</strong></li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Ticagrelor.</li>\n\t\t\t\t<li>Cangrelor: IV drug (used during <span class=\"customMeta\" data-dictid=\"b2fb1a3a5416927771953ea4fa15e1\">percutaneous</span> <span class=\"customMeta\" data-dictid=\"7c48bba0a71692777200073b077d94\">transluminal</span> <span class=\"customMeta\" data-dictid=\"bc8bc758371692777185eff2ccabb7\">coronary</span> angiography- PTCA).</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><strong>Clinical Uses of <span class=\"customMeta\" data-dictid=\"923249383b169277718076e76192c8\">ADP</span> <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> blockers: </strong>ACS, PCI, stroke prevention.</p>\n\n<p> </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/jvY9CYcUujKs6xI0S3QV1749057866.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/V8HznPDySudavShGQQhz1749057812.mp3"
    },
    {
      "text": "A 58-year-old man presents with a sudden onset of severe chest pain radiating to his left arm. He is diaphoretic and appears anxious. His medical history includes hypertension and hyperlipidemia. An ECG shows ST-segment elevation in the anterior leads, and laboratory tests reveal elevated troponin levels. The cardiologist considers initiating therapy with prasugrel.\n\nWhich of the following conditions is a contraindication for the use of prasugrel in this patient?",
      "choices": [
        {
          "id": 0,
          "text": "Hypertension"
        },
        {
          "id": 1,
          "text": "Hyperlipidemia"
        },
        {
          "id": 2,
          "text": "History of ischemic stroke"
        },
        {
          "id": 3,
          "text": "Diabetes mellitus"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct answer: C) History of ischemic stroke</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>From the given history, the patient likely has developed <span class=\"customMeta\" data-dictid=\"4cdc8161f71692777180df58cafa93\">acute</span> MI.</p>\n\n<ul>\n\t<li><strong>ADP <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> blockers</strong>, such as clopidogrel, prasugrel, and ticagrelor, are <span class=\"customMeta\" data-dictid=\"257da9409416927771815e64ee5df1\">antiplatelet</span> agents used to reduce the risk of thrombotic events in patients with <span class=\"customMeta\" data-dictid=\"4cdc8161f71692777180df58cafa93\">acute</span> <span class=\"customMeta\" data-dictid=\"bc8bc758371692777185eff2ccabb7\">coronary</span> syndromes, including MI.\n\n\t<ul>\n\t\t<li>Inhibit <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> <span class=\"customMeta\" data-dictid=\"a00e90be0416927771803afbbf099b\">aggregation</span> by <span class=\"customMeta\" data-dictid=\"9dc12b322016927771830dff673eeb\">blocking</span> the <span class=\"customMeta\" data-dictid=\"923249383b169277718076e76192c8\">ADP</span> receptors on <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> cell membranes, thereby preventing <span class=\"customMeta\" data-dictid=\"5e0b40993316927771844dbf382689\">clot</span> formation.</li>\n\t\t<li>While ticlopidine and clopidogrel can be given in both MI and stroke, prasugrel, ticagrelor, and cangrelor are used only in MI and are contraindicated in patients with a history stroke due to the increased risk of severe <span class=\"customMeta\" data-dictid=\"41e858bf2816927771836d46c619b9\">bleeding</span> (risk of hemorrhagic stroke).</li>\n\t</ul>\n\t</li>\n</ul>\n\n<p> </p>\n\n<p>Hypertension, hyperlipidemia, and <span class=\"customMeta\" data-dictid=\"b6a934c67b16927771868fca92baf9\">diabetes mellitus</span> <strong>(Option A,B, and D)</strong> are not contraindications for <span class=\"customMeta\" data-dictid=\"923249383b169277718076e76192c8\">ADP</span> <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> blockers. Many patients with <span class=\"customMeta\" data-dictid=\"4cdc8161f71692777180df58cafa93\">acute</span> <span class=\"customMeta\" data-dictid=\"bc8bc758371692777185eff2ccabb7\">coronary</span> syndrome also have hypertension, hyperlipidemia, and diabetes and <span class=\"customMeta\" data-dictid=\"923249383b169277718076e76192c8\">ADP</span> <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> blockers can be safely used in these patients.</p>\n\n<p> </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/ehryUrpRqBg3vDY5WinE1749057978.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/t3QbloRvh4I0PK8z0Fmc1749057921.mp3"
    },
    {
      "text": "A 60-year-old male with a history of stable angina is currently on a regimen that includes aspirin and nitrates. His cardiologist decides to add a new medication to his treatment plan to prevent thrombotic events further. After a few weeks, the patient reports increased episodes of chest pain, particularly during physical exertion. The cardiologist suspects that it might be coronary steal syndrome.\n\nWhich of the following medications is most likely responsible?",
      "choices": [
        {
          "id": 0,
          "text": "Pentoxifylline"
        },
        {
          "id": 1,
          "text": "Dipyridamole"
        },
        {
          "id": 2,
          "text": "Cilostazol"
        },
        {
          "id": 3,
          "text": "Aspirin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct answer: B) Dipyridamole</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<ul>\n\t<li>Dipyridamole, <strong>a PDE-3 Inhibitor</strong>, is known to cause <span class=\"customMeta\" data-dictid=\"bc8bc758371692777185eff2ccabb7\">coronary</span> steal syndrome, which can exacerbate <span class=\"customMeta\" data-dictid=\"030cd51b341692777181d15302c8d4\">angina</span> by dilating the relatively constricted arterioles of the healthy myocardium, leading to redistribution of <span class=\"customMeta\" data-dictid=\"82cc227a1c169277718387905b50c6\">blood flow</span> away from the ischemic myocardium.</li>\n\t<li>Dipyridamole and other PDE-3 inhibitors(Pentoxifylline, Cilostazol) act by <strong>blocking PDE-3 Receptors on platelets thereby increasing cAMP and inhibiting <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> recruitment. </strong>However, <span class=\"customMeta\" data-dictid=\"1ab668161b16927771865ebc1c2dde\">Dipyridamole</span> is approved for secondary prevention of stroke when it is<strong> combined with aspirin. </strong></li>\n</ul>\n\n<p><br />\n </p>\n\n<p><strong>PDE-3 Inhibitors</strong></p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Drug</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Common uses</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Notes</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Pentoxifylline</p>\n\n\t\t\t<p><strong>(Option A)</strong></p>\n\t\t\t</td>\n\t\t\t<td rowspan=\"3\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\"><br />\n\t\t\t<br />\n\t\t\t<br />\n\t\t\t<br />\n\t\t\t \n\t\t\t<p>Used as an add-on drug to <span class=\"customMeta\" data-dictid=\"deba671f4716927771828c95a320e5\">aspirin</span> in cases of Stroke and Buerger's disease</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li> Improves blood <span class=\"customMeta\" data-dictid=\"337d16dac5169277718474b97f6e4a\">circulation</span> (rheological agent)</li>\n\t\t\t\t<li> Increases <span class=\"customMeta\" data-dictid=\"d6c754309d16927771874142ec8ca4\">elasticity</span> of RBCs</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Cilostazol</p>\n\n\t\t\t<p><strong>(Option C)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">-</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Dipyridamole</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p> Dipyridamole is approved for secondary prevention of stroke when it is combined with aspirin</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>\n\n<p> </p>\n\n<p> </p>\n\n<p><br />\n </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/eF3U2lTO3SvUUANIHfSG1749062211.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/QPhlRKWn8Do3cfNzNe8x1749062151.mp3"
    },
    {
      "text": "A 55-year-old male with a history of myocardial infarction is being evaluated for ongoing chest pain and shortness of breath. The patient's current medication regimen includes aspirin, a beta-blocker, and a statin. The cardiologist considers adding a Phosphodiesterase 3 (PDE-3) inhibitor to further manage the patient's symptoms but recalls that certain PDE-3 inhibitors are contraindicated in patients with myocardial infarction.\n\nWhich is the correct reason for PDE-3 inhibitors being contraindicated in patients with a history of myocardial infarction?",
      "choices": [
        {
          "id": 0,
          "text": "They increase the risk of bleeding."
        },
        {
          "id": 1,
          "text": "They cause severe hypotension."
        },
        {
          "id": 2,
          "text": "They may inhibit PDE3 in the heart, leading to increased cardiac stimulation and oxygen demand."
        },
        {
          "id": 3,
          "text": "They can cause bradycardia and heart block."
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct answer: C) They may <span class=\"customMeta\" data-dictid=\"6b3de87b7c16927771901326efbcd2\">inhibit</span> PDE3 in the heart, leading to increased <span class=\"customMeta\" data-dictid=\"e1fb96fd2416927771830dfed40e14\">cardiac</span> <span class=\"customMeta\" data-dictid=\"7f3792072b1692777199fd8e2c4f59\">stimulation</span> and oxygen demand.</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>PDE-3 inhibitors increase cAMP levels, which can lead to <strong>increased <span class=\"customMeta\" data-dictid=\"e1fb96fd2416927771830dfed40e14\">cardiac</span> stimulation</strong>. In patients with a history of myocardial infarction, this increased <span class=\"customMeta\" data-dictid=\"e1fb96fd2416927771830dfed40e14\">cardiac</span> <span class=\"customMeta\" data-dictid=\"7f3792072b1692777199fd8e2c4f59\">stimulation</span> can <strong>elevate heart rate and oxygen demand</strong>, potentially worsening the patient's condition and increasing the risk of adverse <span class=\"customMeta\" data-dictid=\"e1fb96fd2416927771830dfed40e14\">cardiac</span> events.</p>\n\n<ul>\n\t<li>While PDE-3 inhibitors do have some effects on blood platelets and may be used to prevent <span class=\"customMeta\" data-dictid=\"5e0b40993316927771844dbf382689\">clot</span> formation, the primary concern in myocardial <span class=\"customMeta\" data-dictid=\"77aed446d2169277719007f42bf052\">infarction</span> patients is not an increased risk of <span class=\"customMeta\" data-dictid=\"41e858bf2816927771836d46c619b9\">bleeding</span> but rather the increased <span class=\"customMeta\" data-dictid=\"e1fb96fd2416927771830dfed40e14\">cardiac</span> workload and oxygen demand. (<strong>Option A)</strong></li>\n\t<li>PDE-3 inhibitors can cause <span class=\"customMeta\" data-dictid=\"9402185d4b1692777189cb62891ff1\">hypotension</span> as a <span class=\"customMeta\" data-dictid=\"79506a117416927771988bbe7a8302\">side effect</span> due to their vasodilatory effects, but this is not the primary reason they are contraindicated in patients with a history of myocardial infarction. (<strong>Option B</strong>)</li>\n\t<li>PDE-3 inhibitors are more likely to cause <span class=\"customMeta\" data-dictid=\"af1cd978a41692777200da2f67bf22\">tachycardia</span> (increased heart rate) rather than <span class=\"customMeta\" data-dictid=\"c933e533971692777183b764d960d0\">bradycardia</span> (decreased heart rate). <span class=\"customMeta\" data-dictid=\"40b788dd6916927771888a3ea6872f\">Heart block</span> is also not a typical concern with PDE-3 inhibitors. (<strong>Option D)</strong></li>\n</ul>\n\n<p> </p>\n\n<p> </p>\n\n<p><br />\n </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/p6wJ7tnIotAnhjDkm3uH1749062354.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/qSnFfHYvuLX4wtqKJeZX1749062286.mp3"
    },
    {
      "text": "A 65-year-old male patient with a history of chronic kidney disease presents to the emergency department with severe chest pain. An electrocardiogram (ECG) confirms an acute myocardial infarction (MI). The cardiologist decides to proceed with percutaneous coronary intervention (PCI) and considers using a glycoprotein IIb/IIIa inhibitor to prevent further thrombotic events during the procedure.\n\nGiven the patient's renal condition, which glycoprotein IIb/IIIa inhibitor is most appropriate for this patient?",
      "choices": [
        {
          "id": 0,
          "text": "Eptifibatide"
        },
        {
          "id": 1,
          "text": "Abciximab"
        },
        {
          "id": 2,
          "text": "Tirofiban"
        },
        {
          "id": 3,
          "text": "Aspirin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct answer: B) Abciximab</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<ul>\n\t<li>Abciximab is a <span class=\"customMeta\" data-dictid=\"b2b82438d6169277719287eb450079\">monoclonal</span> <span class=\"customMeta\" data-dictid=\"9d7a12cab116927771811a0079086d\">antibody</span> that inhibits <span class=\"customMeta\" data-dictid=\"6c9fa3a73216927771888299c86e08\">glycoprotein</span> IIb/IIIa. It is safe in <span class=\"customMeta\" data-dictid=\"b9356afdba16927771979d068c6587\">renal</span> failure as it is not renally eliminated and does not require <span class=\"customMeta\" data-dictid=\"b5bd69c9791692777186a40f45ffb6\">dosage</span> adjustment in <span class=\"customMeta\" data-dictid=\"b9356afdba16927771979d068c6587\">Renal</span> patients.</li>\n\t<li>GpIIb/IIIa inhibitors are also known as <strong>Antiaggregant </strong>or <strong>Anti-integrin drugs</strong> as GpIIb/IIIa is an <span class=\"customMeta\" data-dictid=\"03f1cf44de16927771903f3806de84\">integrin</span> molecule.</li>\n</ul>\n\n<p> </p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td colspan=\"4\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">GpIIb/IIIa inhibitors</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><strong>Drug</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><strong>Structure</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><strong>Common Uses</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><strong>Route</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Abciximab</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Monoclonal antibody</p>\n\t\t\t</td>\n\t\t\t<td rowspan=\"3\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Acute attack of MI</p>\n\n\t\t\t<p style=\"text-align:center\"> </p>\n\n\t\t\t<p style=\"text-align:center\">Stroke</p>\n\n\t\t\t<p style=\"text-align:center\"> </p>\n\n\t\t\t<p style=\"text-align:center\">Stent replacement <strong>(Percutaneous <span class=\"customMeta\" data-dictid=\"7c48bba0a71692777200073b077d94\">transluminal</span> <span class=\"customMeta\" data-dictid=\"bc8bc758371692777185eff2ccabb7\">coronary</span> angioplasty)</strong></p>\n\t\t\t</td>\n\t\t\t<td rowspan=\"3\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><br />\n\t\t\t </p>\n\n\t\t\t<p style=\"text-align:center\">i.v.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Eptifibatide</p>\n\n\t\t\t<p style=\"text-align:center\"><strong>(Option A)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Peptide molecule</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Tirofiban</p>\n\n\t\t\t<p style=\"text-align:center\"><strong>(Option C)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Non-peptide molecule</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><br />\n<strong>Eptifibatide</strong> and <strong>Tirofiban </strong>are renally cleared and requires dose adjustment in patients with <span class=\"customMeta\" data-dictid=\"b9356afdba16927771979d068c6587\">renal</span> impairment.</p>\n\n<p>Also, <strong>Aspirin</strong> <strong>(Option D)</strong> is an <span class=\"customMeta\" data-dictid=\"257da9409416927771815e64ee5df1\">antiplatelet</span> agent commonly used in the management of <span class=\"customMeta\" data-dictid=\"4cdc8161f71692777180df58cafa93\">acute</span> <span class=\"customMeta\" data-dictid=\"bc8bc758371692777185eff2ccabb7\">coronary</span> syndromes and for secondary prevention of thrombotic events. However, it is not a <span class=\"customMeta\" data-dictid=\"6c9fa3a73216927771888299c86e08\">glycoprotein</span> IIb/IIIa inhibitor.</p>\n\n<p> </p>\n\n<p> </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/vRzaxVA6h1ykrUsQXHI81749062503.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/rWXSb6746YUCcRpabLfg1749062431.mp3"
    },
    {
      "text": "Which of the following statements about newer antiplatelet drugs is incorrect?",
      "choices": [
        {
          "id": 0,
          "text": "Vorapaxar is a PAR (Protease Activating Receptor) inhibitor."
        },
        {
          "id": 1,
          "text": "Blocking PAR receptors on platelets prevents the attachment of thrombin, leading to no platelet aggregation."
        },
        {
          "id": 2,
          "text": "Dazoxiben is a thromboxane A2 synthase inhibitor."
        },
        {
          "id": 3,
          "text": "Dazoxiben is recently approved as an add-on drug to aspirin in myocardial infarction (MI)."
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Correct answer: D) Dazoxiben is recently approved as an add-on drug to <span class=\"customMeta\" data-dictid=\"deba671f4716927771828c95a320e5\">aspirin</span> in myocardial <span class=\"customMeta\" data-dictid=\"77aed446d2169277719007f42bf052\">infarction</span> (MI).</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>Vorapaxar, not Dazoxiben, has been recently approved as an add-on drug to <span class=\"customMeta\" data-dictid=\"deba671f4716927771828c95a320e5\">aspirin</span> in MI.</p>\n\n<p>Dazoxiben is still under trial for MI and has not been approved as an add-on drug.</p>\n\n<p> </p>\n\n<p><strong>Newer Anti-platelet Drugs:</strong></p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:613px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><strong>Drug Name</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><strong>Drug Type</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><strong>Mechanism of Action</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><strong>Approval Status</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Vorapaxar</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">PAR (Protease Activating Receptor) inhibitor</p>\n\n\t\t\t<p style=\"text-align:center\"><strong>(Option A)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Blocks PAR <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> on platelets, preventing <span class=\"customMeta\" data-dictid=\"ac7e1f394f1692777200c5bb11e4d8\">thrombin</span> <span class=\"customMeta\" data-dictid=\"ccd357daaf16927771825777ea6a0d\">attachment</span> and <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> aggregation</p>\n\n\t\t\t<p style=\"text-align:center\"><strong>(Option B)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Recently approved as an add-on drug to <span class=\"customMeta\" data-dictid=\"deba671f4716927771828c95a320e5\">aspirin</span> in MI</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Dazoxiben</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Thromboxane A2 <span class=\"customMeta\" data-dictid=\"d2bd91ccac169277719941254e1795\">synthase</span> inhibitor</p>\n\n\t\t\t<p style=\"text-align:center\"><strong>(Option C)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Arachidonic Acid (via COX-1 enzyme)</p>\n\n\t\t\t<p style=\"text-align:center\">↓</p>\n\n\t\t\t<p style=\"text-align:center\">Prostaglandin G2 (via Thromboxane A2 Synthase)</p>\n\n\t\t\t<p style=\"text-align:center\">↓</p>\n\n\t\t\t<p style=\"text-align:center\">Thromboxane A2 (TxA2)</p>\n\n\t\t\t<p style=\"text-align:center\">Dazoxiben blocks <strong>Thromboxane A2 Synthase</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Under trial for MI</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/fJsdM7e1syQs6o1t8qer1749062611.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/6bTnuIrFVChnknmKNyKR1749062565.mp3"
    },
    {
      "text": "A 45-year-old female presents to the clinic with a history of easy bruising, petechiae, and prolonged bleeding from minor cuts. Laboratory tests reveal a significantly low platelet count, and she is diagnosed with idiopathic thrombocytopenic purpura (ITP). The physician decides to start treatment to increase her platelet count.\n\nWhich of the following pro-platelet drugs is most appropriate for treating this patient's condition?",
      "choices": [
        {
          "id": 0,
          "text": "Vorapaxar"
        },
        {
          "id": 1,
          "text": "Oprelvekin"
        },
        {
          "id": 2,
          "text": "Romiplostim"
        },
        {
          "id": 3,
          "text": "Abciximab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct answer: C) Romiplostim</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p><strong>Romiplostim</strong> is a <span class=\"customMeta\" data-dictid=\"b566321fe8169277719716b1cf4df0\">recombinant</span> <span class=\"customMeta\" data-dictid=\"a1b06f401f1692777203a53393ba98\">form</span> of <span class=\"customMeta\" data-dictid=\"b084a2ed0d1692777200e64e4a9b54\">thrombopoietin</span> given as a <strong>subcutaneous <span class=\"customMeta\" data-dictid=\"3509997646169277719014053aa74d\">injection</span> </strong>specifically for the treatment of <span class=\"customMeta\" data-dictid=\"4acddc3cf5169277718996440e2e14\">idiopathic</span> thrombocytopenic <span class=\"customMeta\" data-dictid=\"0acd34c758169277719644923511e5\">purpura</span> (ITP). It acts by increasing <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> production by mimicking <span class=\"customMeta\" data-dictid=\"b084a2ed0d1692777200e64e4a9b54\">thrombopoietin</span> & stimulating megakaryocytes in the bone marrow.</p>\n\n<p>Treatment options for ITP:</p>\n\n<ul>\n\t<li><strong>Observation</strong> for mild cases.</li>\n\t<li><strong>Corticosteroids and IVIG</strong> for moderate to severe cases.</li>\n\t<li><strong>Splenectomy</strong> for <span class=\"customMeta\" data-dictid=\"3790c638ab16927771970a0a41d3ab\">refractory</span> <span class=\"customMeta\" data-dictid=\"57ddcfb8ec1692777190b76f23c2e5\">ITP</span> or when other treatments fail.</li>\n</ul>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td colspan=\"4\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><strong>Pro-Platelet Drugs</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><strong>Drug Name</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><strong>Drug Type</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><strong>Route</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\"><strong>Uses</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Romiplostim</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Recombinant <span class=\"customMeta\" data-dictid=\"a1b06f401f1692777203a53393ba98\">form</span> of thrombopoietin</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Subcutaneous injection</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Treatment of <span class=\"customMeta\" data-dictid=\"4acddc3cf5169277718996440e2e14\">idiopathic</span> thrombocytopenic <span class=\"customMeta\" data-dictid=\"0acd34c758169277719644923511e5\">purpura</span> (ITP)</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Eltrombopag</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Thrombopoietin <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> agonist</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Oral</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Treatment of <span class=\"customMeta\" data-dictid=\"57ddcfb8ec1692777190b76f23c2e5\">ITP</span> and chronic liver disease</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Oprelvekin</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Recombinant <span class=\"customMeta\" data-dictid=\"a1b06f401f1692777203a53393ba98\">form</span> of IL-11</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">Subcutaneous injection</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p style=\"text-align:center\">DOC in chemotherapy-induced thrombocytopenia</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>\n\n<p><strong>Vorapaxar (Option A): </strong> is an <span class=\"customMeta\" data-dictid=\"257da9409416927771815e64ee5df1\">antiplatelet</span> drug that inhibits the PAR-1 receptor, used to reduce thrombotic <span class=\"customMeta\" data-dictid=\"e2b5f013011692777183ea1b11ed9c\">cardiovascular</span> events, and is not indicated for increasing <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> count in ITP.</p>\n\n<p><strong>Oprelvekin (Option B):</strong> is a <span class=\"customMeta\" data-dictid=\"b566321fe8169277719716b1cf4df0\">recombinant</span> <span class=\"customMeta\" data-dictid=\"a1b06f401f1692777203a53393ba98\">form</span> of <span class=\"customMeta\" data-dictid=\"e5391c3f5e1692777190b226153f77\">interleukin-11</span> (IL-11) used for the prevention of severe <span class=\"customMeta\" data-dictid=\"fc28c74bb716927772003aee4aa43c\">thrombocytopenia</span> during chemotherapy. It is not the primary choice for ITP.</p>\n\n<p><strong>Abciximab (Option D):</strong> is a <span class=\"customMeta\" data-dictid=\"6c9fa3a73216927771888299c86e08\">glycoprotein</span> IIb/IIIa <span class=\"customMeta\" data-dictid=\"b5fb56a28b1692777190396ae8b625\">inhibitor</span> used in <span class=\"customMeta\" data-dictid=\"4cdc8161f71692777180df58cafa93\">acute</span> <span class=\"customMeta\" data-dictid=\"bc8bc758371692777185eff2ccabb7\">coronary</span> syndromes and during <span class=\"customMeta\" data-dictid=\"0a263e27891692777194fb743083f9\">PCI</span> to prevent <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> aggregation, and is not indicated for treating ITP.</p>\n\n<p> </p>\n\n<p> </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/UaYbEHuq5O63XxfbY7f41747297647.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/5Fyy0sj6Ko2ery2F7OP31747297582.mp3"
    },
    {
      "text": "Which of the following drugs is approved for immune thrombocytopenia (ITP) ?",
      "choices": [
        {
          "id": 0,
          "text": "Fostamatinib"
        },
        {
          "id": 1,
          "text": "Bosutinib"
        },
        {
          "id": 2,
          "text": "Oprelvekin"
        },
        {
          "id": 3,
          "text": "Erlotinib"
        }
      ],
      "correct_choice_id": 0,
      "solution": "<p><strong>Correct answer: A) Fostamatinib</strong></p>\n\n<p><strong>Explanation:</strong></p>\n\n<p>Fostamatinib is approved for Chronic immune thrombocytopenia</p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Drug </strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Class</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>Use</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Fostamatinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>BTK inhibitor</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Chronic immune thrombocytopenia</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Bosutinib</p>\n\n\t\t\t<p><strong>(Option B)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Tyrosine <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> inhibitor</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Chronic, accelerated, or blast-phase Ph+ <span class=\"customMeta\" data-dictid=\"32c39405871692777184d06d6c01ab\">CML</span> with resistance or <span class=\"customMeta\" data-dictid=\"7794e5fd7a1692777190ee626ede62\">intolerance</span> to prior therapy</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Oprelvekin</p>\n\n\t\t\t<p><strong>(Option C)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Thrombopoietic growth factor (recombinant IL-11)</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Patients undergoing <span class=\"customMeta\" data-dictid=\"8602c4b260169277718439bb122cb0\">chemotherapy</span> for non-myeloid malignancies with severe thrombocytopenia</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Erlotinib</p>\n\n\t\t\t<p><strong>(Option D)</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>EGFR inhibitor</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<ul>\n\t\t\t\t<li>Patients with advanced or metastatic Non-Small Cell Lung Cancer after failure of platinum-based <span class=\"customMeta\" data-dictid=\"8602c4b260169277718439bb122cb0\">chemotherapy</span> treatment</li>\n\t\t\t</ul>\n\n\t\t\t<ul>\n\t\t\t\t<li>Newly diagnosed Non-Small Cell Lung Cancer patients with EGFR mutations</li>\n\t\t\t\t<li>In combination with gemcitabine for the treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p> </p>\n\n<p> </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": "https://image.prepladder.com/content/LVooGrEW9S2UsCkVKfaQ1749062723.mp3",
      "explanation_audio_hin": "https://image.prepladder.com/content/0irAi8E3mWGfyjIgJraJ1749062670.mp3"
    }
  ]
}